

1 Distinct and synergistic immunological responses to SARS-CoV-2 and
2 *Mycobacterium tuberculosis* during co-infection identified by single-cell-
3 RNA-seq

4 Dylan Sheerin^{1,2,*}, Thanh Kha Phan^{1,3}, Emily M. Eriksson^{2,4}, COVID PROFILE Consortium, Anna
5 K. Coussens^{1,2,5,*}

6 ¹ Infectious Diseases and Immune Defence Division, Walter and Eliza Hall Institute of Medical
7 Research, VIC 3052, Australia

8 ² Department of Medical Biology, The University of Melbourne, VIC 3052, Australia

9 ³ La Trobe Institute for Molecular Science, Department of Biochemistry and Chemistry, School of
10 Agriculture, Biomedicine and Environment, La Trobe University, Melbourne, Australia

11 ⁴ Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research,
12 VIC 3052, Australia

13 ⁵ Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular
14 Medicine, Department of Pathology, University of Cape Town, South Africa

15 *** Correspondence:**

16 Dylan Sheerin; sheerin.d@wehi.edu.au

17 Anna Coussens; coussens.a@wehi.edu.au

18

19 **Keywords: Tuberculosis, COVID-19, whole blood, scRNA-seq, apoptosis, cell death, TNF,**
20 **interferon, HIVE.**

21 **Abstract**

22

23 COVID-19 and tuberculosis (TB) exhibit similar symptomatic presentation, clinical parameters and
24 co-diagnosis increases COVID-19 mortality yet there is limited understanding of the mechanisms
25 underlying their immunopathogenic interactions. Here we show by single-cell RNA-sequencing of
26 18,990 cells from whole blood uninfected or infected with *Mycobacterium tuberculosis* (*Mtb*),
27 SARS-CoV-2, or both pathogens, their shared, distinct, and synergistic immunological interactions.
28 The greatest transcriptional divergence occurred within monocytes and two neutrophil subsets at
29 early timepoints of infection. Co-infection had the greatest synergistic effect 24 hours post-infection
30 including enrichment of IFN- γ and TNF production, whilst 96 hours post-infection *Mtb*, SARS-CoV-
31 2 and co-infection shared considerable pathway overlap. SARS-CoV-2 infection alone resulted in
32 widespread cell death 96 hours post-infection, whilst *Mtb* and co-infection had enhanced cell survival
33 at 96 hrs, sharing negative regulation of extrinsic apoptosis. Our findings elucidate potential
34 pathways for targeted host-directed therapies, which is particularly crucial for settings where these
35 pathogens are now endemic.

36

37

38

39

40 **Introduction**

41 The COVID-19 pandemic has had a substantial impact on global progress towards tuberculosis
42 (TB) elimination, primarily through disruptions to TB diagnosis and treatment services^{1,2}. There
43 was a precipitous drop in TB notifications in 2020 and, according to numbers derived from the most
44 recent World Health Organization report, annual deaths from TB have increased between 2019 and
45 2021 for the first time since 2005³, reversing a trend of slow but sustained decline. Beyond
46 impacting TB health services, the Global Tuberculosis Network conducted a prospective multi-
47 country register-based cohort study involving 175 centres across 37 countries, identifying 767
48 dually diagnosed TB/COVID-19 patients which provided evidence that TB patients suffer worse
49 outcomes when co-infected by COVID-19⁴. They found that TB/COVID-19 patients experienced
50 11.1% mortality, compared to 1-2% for COVID-19 alone. A large multi-variate analysis of
51 3,460,932 patients in South Africa found that current and previous TB increased COVID-19
52 mortality with adjusted hazard ratios of 2.7 and 1.5, respectively⁵. Despite these epidemiological
53 findings, the immunopathologic interaction between TB and COVID-19 that increases mortality
54 risk remains poorly understood.

55 The effects of co-infection with *Mycobacterium tuberculosis* (*Mtb*) and SARS-CoV-2 on host
56 immune responses have scarcely been explored in the literature to date. Most published studies have
57 focused on the impact of co-infection on antigen-specific responses to *Mtb* and SARS-CoV-2.
58 These studies have reported that active (clinical) TB limits interferon (IFN)- γ responses to SARS-
59 CoV-2 antigen *in vitro*⁶, that COVID-19 patients have lower levels of *Mtb*-specific CD4+ T cells⁷
60 and that “latent” TB infection alters humoral responses to SARS-CoV-2 infection⁸ and *vice versa*⁹.
61 A mouse study of *Mtb*/SARS-CoV-2 co-infection demonstrated alteration of the cytokine profile
62 and loss of granulomatous control of *Mtb* in the lung, leading to *Mtb* dissemination¹⁰. Most recently,
63 immune profiling of TB/COVID-19 co-infected patients revealed significant impairment of antigen-
64 specific responses to the virus and diminished *in vitro* *Mtb*-specific responses in co-infected patients

65 compared with those with TB-only¹¹. Taken together, these data demonstrate an alteration of the
66 ability of the host to respond to and control *Mtb* and/or SARS-CoV-2 in the event of co-infection,
67 prompting further exploration of the underlying immunological pathways.

68 We previously performed a patient-level meta-analysis of published COVID-19 immune cell
69 signatures on publicly available TB RNA-seq datasets to identify potential immunological hotspots
70 that could exacerbate disease, identifying neutrophil, monocyte, lung macrophage subpopulations,
71 interferon and complement signalling particularly shared between severe COVID-19 and active and
72 subclinical TB¹². However, a detailed exploration of the responses to genuine co-infection in
73 humans was lacking. We therefore elected to study these responses in human whole blood at single-
74 cell (sc) resolution by subjecting blood samples from four healthy adults to *ex vivo* infection with
75 *Mtb* and/or SARS-CoV-2 for subsequent scRNA-seq at 24 and 96 hours post-infection (p.i.). By
76 defining longitudinal gene expression changes induced by each infectious agent, relative to
77 uninfected samples, and comparing these responses with co-infected samples, we were able to
78 discern unique aspects of the immune response to each pathogen and which responses are
79 exacerbated by co-infection. The present study provides the most comprehensive overview of the
80 immunological interaction between these two globally significant pathogens to date.

81

82 **Results**

83 **Pathogen-specific changes in immune cell proportions recovered from peripheral blood** 84 **emerge over the course of *ex vivo* infection**

85 Peripheral blood collected from four healthy donors, all COVID-19 vaccinated, two with
86 documented PCR-positive mild/moderate COVID-19 and two without were collected on different
87 days and cultured either uninfected or infected with *Mtb*, SARS-CoV-2, or both pathogens
88 simultaneously for 24 and 96 hours. Cells were captured, preserved and stored in HIVE scRNA-seq

89 devices and then batch processed for scRNA-seq library preparation and sequencing. Following
90 acquisition of scRNA-seq data, quality control analysis was first performed on the raw scRNA-seq
91 data acquired from each individual sample from our 8 biological conditions: uninfected, *Mtb*-only,
92 SARS-CoV-2-only (SARS-only) and co-infection, at 2 time points. Each sample was then filtered
93 to exclude cells with <500 genes/transcripts and >15% of reads mapping to mitochondrial genes
94 (indicative of dying cells). This resulted in total cell counts ranging from 367–3,894 (median
95 2,340), and an overall total of 18,990 cells (Table 1). Normalisation and feature selection were
96 performed prior to data integration, and dimensionality reduction was subsequently performed on
97 the integrated data. *ANPEP*, a gene which encodes alanine aminopeptidase, a receptor known to
98 facilitate the binding and entry of coronaviruses, was the top gene contributing to the first principal
99 component (PC1) of the data (Fig. 1a). In addition to multiple genes involved in macrophage and
100 endothelial cell adhesion and migration, *RAB31*, which encodes a GTPase implicated in the
101 maturation of phagosomes which engulf *Mtb*, was among the top 10 genes contributing to PC1 (Fig.
102 1a).

103 Fourteen clusters were identified based on underlying gene expression differences in the integrated
104 data which were broadly categorised by applying cell type annotation into eight distinct immune
105 cell populations (Fig. 1b). The integrated data were then split by infection condition at each time
106 point to begin comparing cell clusters (Fig. 1c). Yields for each cell type were similar overall
107 between 24 hours and 96 hours p.i. for the uninfected and *Mtb*-only samples, but there was fewer
108 cells recovered in the SARS-only and co-infected samples at 96 h p.i (Fig. 1c, Table 1). SARS-only
109 had the lowest number of cells recovered at this time point, with just 367 remaining after quality
110 filtering (Table 1). Neutrophils made up a greater proportion of the SARS-only and co-infected
111 samples at 24 hours p.i. (68% and 52% of recovered cells, respectively) compared to uninfected and
112 *Mtb*-only (27% and 23%, respectively), with SARS-only having the lowest proportions of CD4+ T
113 cells, CD8+ T cells, B cells and natural killer (NK) cells of all four conditions (Supplementary Fig.


114 1). This represented a 17% and 12% increase for each of the two identified neutrophil populations
115 in the SARS-only samples, relative to the uninfected samples, while the second population
116 accounted for a 33% increase in the co-infected samples (Fig. 1d). At 96 hours p.i., several immune
117 cell populations were more abundant in the *Mtb*-only samples relative to the uninfected samples
118 (Fig. 1d, Table 1), including B cells (88%), LPS-responding neutrophils (95%), NK cells (35%) and
119 CD4+ T cells (33%). With the exception of B cells, the later 3 cell types were also all higher in the
120 co-infected samples compared with the SARS-only samples at this timepoint, suggesting *Mtb* may
121 be sustaining their viability.

Table 1. Cell counts for each of the remaining cells belonging to each annotated immune cell population after quality control filtration for each infection condition and timepoint.

| <i>Cell type</i> | 24 hours post-infection | | | | 96 hours post-infection | | | |
|------------------------------------------------|-------------------------|------------------|-------------|-------------|-------------------------|------------------|------------|-------------|
| | Uninfected | <i>Mtb</i> -only | SARS-only | Co-infected | Uninfected | <i>Mtb</i> -only | SARS-only | Co-infected |
| <i>Monocytes</i> | 2158 | 1106 | 904 | 740 | 2601 | 1464 | 190 | 588 |
| <i>Neutrophils</i> (<i>GM-CSF/ IFN-γ</i>) | 451 | 158 | 979 | 318 | 317 | 92 | 38 | 60 |
| <i>Neutrophils (LPS)</i> | 618 | 297 | 1313 | 820 | 93 | 181 | 17 | 56 |
| <i>CD8+ T cells</i> | 304 | 145 | 70 | 87 | 339 | 275 | 47 | 81 |
| <i>CD4+ T cells</i> | 247 | 176 | 47 | 138 | 259 | 344 | 46 | 143 |
| <i>NK cells</i> | 67 | 63 | 17 | 55 | 55 | 74 | 15 | 42 |
| <i>HSC</i> (<i>G-CSF</i>) | 34 | 24 | 48 | 28 | 29 | 34 | 9 | 14 |
| <i>B cells</i> | 15 | 12 | 2 | 15 | 8 | 15 | 5 | 3 |
| Total (18,990 cells) | 3894 | 1981 | 3380 | 2201 | 3701 | 2479 | 367 | 957 |

2

3



124
125

Fig. 1 Global changes to the transcriptome of human whole blood in response to single or dual

126 *Mtb*/SARS-CoV-2 infection. **a** The top 30 genes contributing to the first two principal components
127 (PC) identified by performing dimensionality reduction on the integrated scRNA-seq from all eight
128 conditions/timepoints, across four donors. **b** Uniform manifold approximation and projection
129 (UMAP) plot depicting clustering of all 18,990 cells across all eight conditions/timepoints, from four


130 donors, identified by shared nearest neighbour modularity optimisation. Clusters are here grouped
131 according to either the 14 identified clusters (0-13, left) or one of eight distinct immune cell type
132 annotations (right). **c** UMAP plots depicting clustering of cells separated for the four conditions (x-
133 axis) and two timepoints (y-axis) and coloured by the eight distinct immune cell type annotations.
134 Cell number for each condition/timepoint listed in Table 1. **d** Bar plots depicting the percentage
135 change in cell count for each of the annotated cell clusters relative to the uninfected samples at the
136 same timepoint, for each infection condition. HSC, haematopoietic stem cell; NK, natural killer;
137 SARS, SARS-CoV-2.

138

139 **Distinct immunological pathway enrichment highlights cells responding to infection**

140 For the 14 identified clusters, covering the eight distinct immune cell populations, GO and Reactome
141 biological process (BP) pathway enrichment analyses were performed to determine whether they
142 were associated with distinct immune functions. Pathways were filtered to display the most salient
143 terms in Fig. 2, with the full lists provided in Supplementary Tables 1-2. Clusters 1, 2, 5 and 7 were
144 associated with the greatest number of significantly enriched pathways. While clusters 2 and 5 are
145 both predicted to be neutrophil populations, cluster 2 is characterised by its response to GM-CSF and
146 IFN- γ , whereas cluster 5 is characterised by its greater enrichment of response to LPS. Cluster 5 was
147 found predominantly in the SARS-only and co-infected samples at 24 hours p.i. (Fig. 1c); clusters 3
148 and 6 were also classified as LPS-responding neutrophils but were not associated with statistically
149 significant enrichment of these pathways at this timepoint. The GM-CSF/IFN- γ -responding
150 neutrophils were associated with the largest number of significantly enriched GO pathways and, as
151 predicted by their annotation, they were defined by response to IFN- γ , production of TNF, cytokine
152 signalling, endocytosis and neutrophil migration (Fig. 2a). Furthermore, this cluster was significantly

153 enriched for Reactome pathways denoting IFN- α/β signalling, Fc- γ receptor-dependent phagocytosis
154 and interleukin signalling (Fig. 2b). The genes implicated in the enrichment of the interleukin
155 signalling term included pro-inflammatory mediators and chemokines *SOD2*, *IRAK1*, *PTAFR*, *IL1B*,
156 *SYK*, *TNFRSF1B*, *CXCL2*, *CSF3R*, *HCK*, *CCL3L1*, *GRB2*, *CCL20*, *CDKN1A*, *CXCL1*, *STAT1*,
157 *CCR1*, *MAP3K8*, *IL1R1*, *CXCL10*, *VEGFA*, *IL1A* and *PTPN12*. Conversely, the LPS-responding
158 neutrophils were exclusively significantly enriched for GO pathways indicating metal ion
159 sequestration and homeostasis (*LCN2*, *FTL*, *TFR2*, *LTF*, *PRNP*, *SLC39A7*, *SLC11A1*, *SI00A8* and
160 *SI00A9*), regulation of leukocyte cell-cell adhesion, response to chemokine (also confirmed by
161 Reactome pathway analysis, Fig. 2b), and negative regulation of cell adhesion and IFN- γ production
162 (Fig. 2a). Clusters 1, 7 and 10 represent subsets of monocytes, with clusters 1 and 7 both enriched for
163 antigen processing and presentation via MHC class II. Cluster 7 is exclusively enriched for peptide
164 antigen assembly with MHC class II protein complex, whilst Cluster 1 is exclusively enriched for
165 myeloid leukocyte migration, superoxide anion generation and membrane lipid catabolic process and
166 Cluster 10 is exclusively enriched for foam cell differentiation (*ITGAV*, *PPARG*, *MSR1*, *NR1H3*,
167 *IL18*, *ITGB3* and *LPL*).



168

169 **Fig. 2 Substantial immune pathway enrichment underpins identified cell clusters and exhibits**
 170 **greatest divergence between conditions at 24 hours post-infection.** 14 identified clusters of cells
 171 were consolidated to eight immune cell populations based on cluster annotation. Cell marker genes
 172 were identified by performing a Wilcoxon Rank Sum tests between each of the eight annotated
 173 immune cell populations, irrespective of sample. These differentially expressed gene (DEG) lists
 174 were then subjected to a biological process (BP) enrichment analysis using **a** gene ontology (GO) or
 175 **b** Reactome pathway annotation. False discovery rate-adjusted 2-sided *p*-values are represented by
 176 the shading of data points, while the size corresponds to the number of significant genes (count)
 177 implicated in that pathway. A pseudobulk analysis was performed between infection conditions at
 178 each timepoint by combining cells in each condition and using standard differential expression (DE)
 179 methods, with each of the four composite donor IDs as replicates. Significant DEGs were then

180 subjected to a BP GO enrichment analysis and the overlap in GO terms was assessed by venn
181 diagram at **c** 24 hours and **d** 96 hours post-infection. Co-infected, *M. tuberculosis* (*Mtb*) and SARS-
182 CoV-2 (SARS) infected.

183

184 **Co-infection demonstrates synergistic global immune pathway enrichment at 24 hours, and**
185 **greater shared pathways by 96 hours, of infection**

186 To ascertain whether differences in immunological pathway enrichment existed between each
187 infection condition, compared to uninfected, a pseudobulk analysis was performed using donor IDs
188 as biological replicates and performing differential expression analyses across all cell types between
189 conditions. A similar GO and Reactome pathway enrichment analysis (Fig. 2A-B, Supplementary
190 Table 3-4) was then performed on the significant genes identified (Supplementary Table 5-10).
191 Assessing the unique and overlapping significantly enriched terms revealed distinct aspects of the
192 immune response invoked by each infection condition, at both time points. At 24 hour p.i SARS-only
193 and coinfection shared the greatest overlap in terms (222), compared to only 39 commonly enriched
194 terms between *Mtb*-only and co-infection however, this pattern was switched at 96 hours p.i. with
195 *Mtb*-only and co-infection sharing 114 terms compared to only 62 shared terms between SARS-only
196 and co-infection. This demonstrates that the influence of each pathogen on the transcriptome
197 changes during the course of co-infection, with the influence of *Mtb* increasing during co-infection as
198 it replicates over time.

199 Looking at terms unique to each pathogen, 105 were enriched for *Mtb*-only and 89 for SARS-only at
200 24 hours p.i.. Of the biologically relevant GO terms for this analysis, certain generic immune cell
201 activation pathways and immune effector processes were uniquely enriched in *Mtb*-only infected
202 cells at 24 hours p.i., while B cell activation (GO:0042113), Fc receptor and STAT signalling

203 (GO:0038094, GO:0097696), and several other cell signalling/response to cytokine GO terms were
204 unique to SARS-only infection (Supplementary Table 3). Amongst the 222 enriched terms shared
205 between SARS-only and co-infection at 24 hours p.i. were $\alpha\beta$ T cell activation and differentiation
206 (GO:0046631, GO:0046632), antimicrobial humoral immune response mediated by antimicrobial
207 peptide (GO:0061844), negative regulation of extrinsic apoptotic signalling (GO:2001237),
208 extracellular matrix disassembly (GO:0022617), negative regulation of cell-cell adhesion
209 (GO:0022408), positive regulation of phagocytosis (GO:0050766), regulation of coagulation
210 (GO:0050818), IFN- γ signalling (GO:0034341), IL-1/2/6 production (GO:0032612, GO:0032623,
211 GO:0032635), leukocyte/lymphocyte proliferation (GO:0070661, GO:0046651) and migration
212 (GO:0050900, GO:0072676), antigen processing and presentation (GO:0019882) and defence
213 response to virus (GO:0051607). Amongst, the 39 terms shared between *Mtb*-only and co-infection at
214 24 hours p.i. included seven related to cell cycle/division, and others relating to endothelial cell
215 migration (GO:0043542) and regulation of cell differentiation (GO:0045595, Supplementary Table
216 3).

217 By 96 hour p.i. *Mtb*-only and co-infection were enriched for 114 shared terms including negative
218 regulation of extrinsic apoptotic signalling (GO:2001240) and TNF production (GO:0010804),
219 antigen processing and presentation via MHC class II (GO:0002495), cell death in response to
220 oxidative stress (GO:0036473), iron homeostasis (GO:0006879), endothelial cell migration and
221 proliferation (GO:0043542, GO:0001935), LPS metabolic process (GO:0008653), and reactive
222 nitrogen species (GO:2001057); while SARS-only and co-infection shared 62 terms including
223 myeloid cell differentiation (GO:0030099), pattern recognition receptor/TLR signalling
224 (GO:0002221, GO:0002224) and positive regulation of reactive oxygen species metabolic process
225 (GO:2000379). At 96 hours p.i. *Mtb* infection had only 16 unique terms (of its total 389), including
226 WNT signalling (GO:0016055), whereas SARS-only infection had the largest number of enriched

227 terms and the largest number of unique terms at this time (513 of 834 terms, ~62%, Fig. 2d).
228 However, the unique terms included many variations on terms collectively shared between all three
229 infection conditions at this timepoint (described below) with the additional enrichment of $\alpha\beta$ T cell
230 activation and differentiation (GO:0046631, GO:0046632), ephrin receptor signalling pathway
231 (GO:0048013), Fc epsilon receptor signalling (GO:0038095), granulocyte migration (GO:0097530),
232 intrinsic apoptotic signalling (GO:0097193), macrophage activation (GO:0042116), IL-2/6/8
233 production (GO:0032623, GO:0032635, GO:0032637), monocyte chemotaxis (GO:0002548), and
234 response to IL-1 (GO:0071347) and type I IFN (GO:0034340); many of these terms being shared
235 between SARS-only and co-infection at 24 hours p.i. Thus, over the time course of infection very
236 few of these pathways were unique to SARS-CoV-2 with the majority regulated at one time by both
237 pathogens, just the kinetics varying. Finding the largest enrichment of pathways in the SARS-only
238 infected cells at 96 hours p.i. with this also being the condition with smallest cell recovery, suggests
239 the dominance of the immune response to SARS infection in the absence of *Mtb* co-infection, with
240 the increased cell recovery for co-infected samples perhaps due to survival signals induced by *Mtb*
241 infection.

242 Next, when comparing how the pathogens interact during co-infection, first comparing the similarity
243 between all three conditions (i.e. terms shared with no synergistic effect of co-infection) there were
244 only 18 collectively shared terms at 24 hour p.i (Fig. 2c), all of which were related to generic
245 biological functions and not specific to infection (Supplementary Table 3). By contrast, co-infection
246 was associated with 238 uniquely enriched terms the largest number across all infection conditions at
247 24 hours p.i., indicating the synergistic nature of the response to dual infection, identifying terms not
248 induced by either pathogen alone (Fig. 2c); uniquely enriched terms included IFN- γ and TNF
249 production (GO:0034341, GO:0034612), lymphocyte activation/differentiation (GO:0046649,
250 GO:0030098), NK cell-mediated immunity (GO:0002228), T cell signalling (GO:0050852) and

251 positive regulation of viral process (GO:0048525). However by 96 hours p.i. only 6 terms were
252 unique to the co-infection group, indicating limited synergistic pathway enrichment, but there were
253 now 182 terms common between *Mtb*-only, SARS-only and co-infection (Fig. 2d); these included
254 antimicrobial humoral response, B cell activation, T cell differentiation, reactive oxygen species
255 processes, regulation of viral life cycle, lipoprotein metabolic process, tissue remodeling and receptor
256 mediated endocytosis (Supplementary Table 4). Together this shows that *Mtb* and SARS-CoV-2
257 share a large overlap in immune pathway enrichment which they each induce during infection with
258 early synergism during co-infection.

259 Finally, at 24 hours p.i there were an additional 10 terms commonly enriched in *Mtb*-only and SARS-
260 only, not shared by co-infection, increasing to 77 commonly enriched terms for the two mono-
261 infections at 96 hours p.i. These terms would be independently but not synergistically regulated by
262 each pathogen, and may include pathways where each pathogen has opposing effects such that during
263 co-infection pathway enrichment is lost.

264

265 **Specific differences between infection conditions are most apparent in innate populations and**
266 **within the first 24 hours of infection**


267 To further examine specific differences and overlapping gene expression between the infection
268 conditions a second pseudobulk analysis was performed, this time at the level of annotated immune
269 cells. For each of the infection conditions, immune cell populations were contrasted against the
270 equivalent cell type in the uninfected group for that timepoint. No significant DEGs were detected in
271 the B cell or haemopoietic stem cell (G-CSF) populations, likely due to the small numbers of cells of
272 this type per donor/condition. The LPS-responding neutrophils at 24 hours p.i. were associated with
273 the greatest number of DEGs across all groups (1,470), with the majority of these induced by co-

274 infection and SARS-only (1,260 total, 434 unique, Supplementary Fig. 2), followed next by
275 monocytes (772 total DEG) and neutrophils (GM-CSF) (626 total DEG) at 24 hours p.i. For all cell
276 types with associated differential expression, there were very few DEGs uniquely associated with
277 *Mtb*-only at 24 hours p.i., at which timepoint SARS-only and co-infection induced the greatest DE,
278 while *Mtb*-only and co-infection induced the greatest DE at 96 hours p.i. when SARS-only induced
279 the least DE of all three conditions (Supplementary Fig. 2). This supports a more acute unique
280 transcriptional perturbation associated with SARS-CoV-2 at the initial stages of infection, while *Mtb*
281 induces a response shared by SARS-CoV-2 and co-infection early on which becomes more distinct
282 from SARS-CoV-2 at the later time point after infection is established. The co-infected samples
283 remained highly transcriptionally active throughout both timepoints due to the presence and
284 synergism of both pathogens.

285 Clustering by DEGs identified for monocyte and neutrophil populations generated the cleanest
286 sample clustering by infection condition and timepoint (Fig. 3a compared with NK, CD4+ and CD8+
287 T cell populations (Supplementary Fig. 3). At 24hr p.i monocyte expression clustered together for
288 *Mtb*-only and co-infection, whilst co-infection had the most unique monocyte expression at 96 hours
289 p.i., with *Mtb*-only and SARS-only clustering more closely together at this later timepoint.
290 Conversely, patterns of neutrophil gene expression clustering were most distinct at 24 hours p.i at
291 which time GM-CSF neutrophils shared a similar expression pattern between *Mtb*-only and SARS-
292 only infections, whilst LPS neutrophils clustered together for co-infection and SARS-only.

293 Finally, the functional enrichment underlying these similarities and differences was assessed at each
294 timepoint. At 24 hours p.i., the majority of enriched pathways were shared by SARS-only and co-
295 infected samples and related to type I IFN responses from monocytes, neutrophils and CD4+ and
296 CD8+ T cells, cell activation (IL-15, IL-23, TNF) of monocytes and neutrophils (GM-CSF, RIG-I
297 like receptor signalling of monocytes, neutrophils (GM-CSF) and CD4+ T cells and viral sensing &

298 immunity; IRF2 targets networks for monocytes and both neutrophil subsets (Fig. 3b, Supplementary
299 Table 11). By comparison, there less cell-specific pathway enrichment at 96 hours p.i., with more
300 enrichment at this timepoint shared between *Mtb*-only and co-infection, or all three infection
301 conditions, with monocytes showing the greatest pathway enrichment, particularly for antigen
302 presentation (II & III) and MHC-TLR7-TLR8 cluster, lysosomes in monocytes and both neutrophils
303 and protein synthesis across all cell types, except neutrophils (GM-CSF) (Fig. 3c, Supplementary
304 Table 12).



305
 306 **Fig. 3 Cell-specific immunological pathway enrichment distinguishes single infection conditions**
 307 **and highlights synergistic activation in co-infected samples.** Pseudobulk differential expression
 308 (DE) analysis was performed by splitting samples by annotated cell type and comparing these cell
 309 types from each infection condition with those of the uninfected samples at each timepoint, using
 310 donor IDs as biological replicates. The resultant signatures of significant genes were then used for

311 hierarchical clustering across all samples, represented by the heatmaps in **a**; the heat of the tiles
312 correspond to the row z-score for a particular gene across all samples. Lists of significant genes for
313 each cell type from each condition were subjected to blood transcriptional module analysis to identify
314 significantly enriched pathways associated with immune cells at **b** 24 hours post-infection and **c** 96
315 hours post-infection. False discovery rate-adjusted 2-sided *p*-values are represented by the shading of
316 data points, while the size corresponds to the number of significant genes implicated in that module.

317

318 **Discussion**

319 In the present study, we expand upon our previous work which identified overlapping transcriptional
320 networks of circulating immune cells isolated from TB and COVID-19 patients¹² by delineating host
321 immune cell gene expression programs in response to direct whole blood infection with *Mtb* and
322 SARS-CoV-2 infection. Importantly, we directly compare responses induced by each pathogen alone
323 to what occurs in the context of direct co-infection with both pathogens bringing us closer to an
324 understanding of what is happening at a cellular level during TB/COVID-19 dual presentation. We
325 define the host response pathways underlying differences between immune cell populations reacting
326 to each infection condition across timepoints that appropriately capture innate and adaptive immune
327 cell activity.

328 Despite the extensive use of bulk RNA-seq to study TB disease mechanisms in the blood of patients,
329 there is but one study that defines host responses to *Mtb* by scRNA-seq in this compartment in which
330 they sequenced PBMCs, excluding granulocytes¹³. There is substantial evidence that neutrophil gene
331 expression is an important marker of TB progression¹⁴⁻¹⁶, so any comprehensive characterisation of
332 TB responses in human blood must include them. Despite their absence from a large number of blood
333 scRNA-seq datasets, the COVID-19 scRNA-seq studies that did sequence neutrophils as part of

334 whole blood found them to be an important cell type for distinguishing patients on the basis of
335 disease severity^{17,18}. In our study, two neutrophil clusters emerged based on gene expression markers,
336 neutrophils characterised by their response to GM-CSF/IFN- γ and those with enhanced response to
337 LPS. The later were recovered in greater abundance in SARS-only and co-infected blood at 24 hours
338 p.i, whilst only the GM-CSF neutrophils were enriched uniquely in SARS-only infection. Based on
339 GO enrichment analyses, GM-CSF neutrophils appeared to have greater enrichment of IFN- γ and
340 TNF regulation. These are both key cytokines implicated in *Mtb* control¹⁹⁻²¹, so the fact they are not
341 enriched to the same levels during co-infection, although they were more abundant than in *Mtb*-
342 infection alone, suggests *Mtb* is interfering with their regulation by SARS-CoV-2. We previously
343 identified IFN- γ and TNF signalling in the top 20 shared transcriptional pathways in blood of
344 COVID-19 and TB patients and demonstrated *in vitro* that SARS-CoV-2 infected macrophages
345 increase *TNF* and *IFNG* expression when pre-incubated in the inflammatory milieu of *Mtb* infected
346 macrophages, correlating with increased SARS-CoV-2 transcript levels¹². IFN- γ and TNF have been
347 shown to act synergistically in a mouse model of COVID-19 by increasing inflammatory cell death
348 through a process termed ‘PANoptosis’²². Cell death was also exclusively significantly enriched in
349 these neutrophils in the SARS-only samples at 24 hours p.i.. Given the dramatic cell death observed
350 at 96 hours p.i. in SARS-only and co-infected samples, with greater loss of cell recovery in SARS-
351 only compared with co-infected, it is possible that early production of these cytokines from
352 neutrophils may be one of the mechanisms underpinning this. A number of apoptosis regulation GO
353 terms were significantly enriched in SARS-infected samples, with or without *Mtb* co-infection, at 24
354 hours p.i, including apoptotic cell clearance, extrinsic and intrinsic apoptotic signalling pathways,
355 leukocyte and lymphocyte apoptotic processes and terms associated in the regulation of these
356 pathways (Supplementary Table 3). At 96 hours p.i *Mtb*-only and co-infection shared enrichment of
357 negative regulation of extrinsic apoptosis, which may underpin the increased recovered of cells from
358 co-infected compared to SARS-only infected blood at 96 hours p.i. Caspase 8, the mediator of

359 extrinsic apoptosis, has been identified as a critical factor in triggering inflammatory processes the
360 lead to immunopathology in the lungs of COVID-19 patients²³. Furthermore, caspase 8-dependent T
361 cell apoptosis has been associated with T cell lymphopenia in severe COVID-19 patients, but this
362 process could be prevented *ex vivo* with the use of pan-caspase inhibitors²⁴. Given the critical role of
363 T cells in *Mtb* control, early intervention to prevent T cell death from occurring in co-infected
364 patients may be required to prevent TB disease progression.

365 Three neutrophil and monocyte cluster signatures were the greatest determinant of differences
366 between the three infection conditions based on hierarchical clustering analyses. This ties in with
367 evidence that innate immune cell gene expression, rather than lymphoid cells, marks the greatest
368 divergence between COVID-19 severity across patients¹⁷. Monocytes were the cell type associated
369 with the largest number of significantly enriched pathways, the majority of which were common to
370 SARS-only and co-infected samples, specifically those related to immune activation, type I IFN
371 responses and antigen presentation. Monocytes expressing high levels of HLA-DR and type I IFNs
372 were identified in mild COVID-19 patients in the scRNA-seq study exploring myeloid cell
373 dysregulation¹⁷. It has been shown that the activation status of monocytes are a correlate of COVID-
374 19 prognosis, with inflammatory phenotypes associated with poorer outcomes²⁵. Given that certain
375 circulating monocytes have been identified in TB patients which correlate with disease progression,
376 the induction of these activated, proinflammatory monocytes during co-infection may increase the
377 likelihood of TB disease being advanced in co-infected individuals²⁶. By 96 hours p.i. the greatest
378 number of significantly enriched pathways was associated with and common to monocytes from
379 *Mtb*-only and co-infected samples and these pathways were mostly related to lysosome and antigen
380 presentation.

381 The most striking functional response induced by SARS-only/co-infection was the production of
382 IFNs, particularly those classified as type I (α and β). This observation runs counter to some early

383 human studies in which only low levels of type I IFN were measured in COVID-19 patients,
384 irrespective of disease severity²⁷, and subsequent studies that suggested little in the way of IFN gene
385 expression in peripheral blood from COVID-19 patients but an early transient wave of IFN-
386 stimulated genes (ISGs)^{17,28}. Mouse studies have indicated that the type I IFN response to SARS-
387 CoV-2 contributes more to immunopathology than viral control²⁹. In TB, early expression of ISGs in
388 TB contacts has been linked to disease progression and worsened prognosis^{16,30-32}. Progression from
389 earlier disease states to clinical TB is typically preceded by a wave of ISG expression¹⁶. However,
390 there is also evidence that type I IFN responses can be protective in TB³³, and therefore it is likely
391 that the influence of these IFNs on immune cell composition and pathogenesis has a time-dependent
392 effect over the course of TB disease³⁴. It is plausible that modulation of the type I IFN response in
393 TB patients with a viral co-infection may alter the balance in such a way as to promote TB disease
394 progression. Over- or under-activation of type I IFN responses is also known to contribute to host
395 pathogenesis for viral infections³⁵, so it is equally likely that an existing *Mtb* infection could
396 negatively impact control of SARS-CoV-2 and promote more severe disease manifestations. Our
397 previous patient-level meta-analysis of COVID-19 signatures on TB datasets indicated that IFN gene
398 signatures associated with COVID-19 severity were highly significantly enriched in whole blood of
399 TB progressors and their expression was the strongest correlate of SARS-CoV-2 replication in
400 macrophages¹², suggesting that the existence of a strong TB IFN signature when SARS-CoV-2 co-
401 infection occurs could be a key determinant of poor outcomes for TB patients.

402 SARS-only samples had much lower proportions of CD4+ T cell, CD8+ T cell, B cell and NK cell
403 recovery at 24 hours. Longitudinal profiling of lymphocyte subsets in COVID-19 patients showed
404 that this occurs in patients shortly after symptom onset, when severe patients have lower proportions
405 of these cell types than those with mild infections, and they reach a nadir at 4–6 days post symptom
406 onset³⁶. It has been reported that TB/COVID-19 co-infected patients have lower absolute lymphocyte

407 counts compared with COVID-19 patients⁶. This did not appear to be the case in our study, although
408 co-infected samples had lower proportions of lymphocytes than *Mtb*-only and uninfected samples at
409 24 hours. We also observed a strong IFN signature in CD4+ and CD8+ T cells at 24 hours p.i. in the
410 SARS-only and co-infected samples. A scRNA-seq study of peripheral blood responses in severe
411 COVID-19 patients noted that the most commonly upregulated genes in these patients were ISGs
412 based on their DE comparison with healthy controls³⁷. At 96 hours p.i protein synthesis was
413 commonly significantly enriched across all three infection conditions in CD4+ and CD8+ T cells.
414 Enrichment of this pathway appeared to be mostly driven by expression of cathepsin genes, including
415 *CTSB* and *CTSD*. These genes encode proteases, mainly found in lysosomes, which have been
416 implicated in *Mtb* survival³⁸ and mediating SARS-CoV-2 binding³⁹.

417 The SARS-only samples had a greater proportion of B cells at 96 hours p.i.; several studies have
418 noted an increase in the frequency of plasmablasts in severe COVID-19 patients^{28,40,41}. However, this
419 cell type was not captured at sufficient levels to perform any meaningful comparisons between
420 groups to ascertain its function. NK cell proportions remained consistent in *Mtb*-only samples, as has
421 been observed in TB patients compared even with TB-HIV co-infected patients^{42,43}. Only samples
422 that were *Mtb*-infected had any significant pathway enrichment in NK cells, with enrichment for
423 protein synthesis, including expression of *CTSD* as well as *PSAP* and *TPT1*, at the 96-hour timepoint.
424 There is evidence that NK cell functionality plays a protective role by combating *Mtb* during HIV
425 infection⁴⁴ that may also apply to other co-infections.

426 Our study is limited by the fact that we are studying the responses to pathogens in an artificial *ex vivo*
427 infection model, so we do not recapitulate the natural course of infection, including the recruitment of
428 new immune cells to replenish dying ones. Little is known about the mechanisms underlying human
429 immune responses to the initial stages of *Mtb* infection as it is difficult to ascertain when exactly this
430 occurs, while symptoms and diagnostics allow this to be better determined for SARS-CoV-2

431 infection. Our use of a reagent, TPCK trypsin, to cleave the SARS-CoV-2 spike glycoprotein and
432 allow entry into host cells that do not express or have low levels of ACE2 receptor during initial
433 infection also means that this model is not entirely representative of what occurs *in vivo*. This was
434 done to increase the number of infected cells in our model, over the sort experimental timecourse.
435 Human neutrophils have high levels of ACE2 expression and would be naturally infected and
436 macrophages have been shown to be infected with SARS-CoV-2 in human lung autopsy sections and
437 to be a site for viral replication⁴⁵. We have also shown human macrophages to have increased
438 susceptibility to SARS-CoV-2 infection in the absence of TPCK trypsin addition when incubated in
439 *Mtb* inflammatory milieu¹². Together this suggests there is the potential for ongoing SARS-CoV-2
440 infection of immune cells in our model, following TPCK trypsin removal. As not all cells will be
441 infected, this approach allowed us to induce a reliable bystander response in cells that do not take up
442 the virus that could then be compared between conditions. Despite the fact that SARS-CoV-2
443 transcripts undergo polyadenylation⁴⁶, we were unable to detect any viral transcripts in our count
444 matrices. This may be due to insufficient sequencing depth or the capture efficiency of the scRNA-
445 seq method used. Finally, simultaneous infection with *Mtb* and SARS-CoV-2 is unlikely to occur in
446 most cases. With an established *Mtb* infection prior to SARS-CoV-2 infection more likely to reflect
447 the vast majority of cases, as was observed in the TB/COVID Global Study Group report⁴.
448 Nevertheless, in any co-infected individual there will always be new cells coming into an infection
449 site, so that over time, irrespective of the first infecting pathogen, once both are present then any
450 subsequent sequence of infection can occur.

451 In summary, we provide the first characterisation of human circulating immune cell gene expression
452 changes resulting from direct *Mtb* and SARS-CoV-2 co-infection. We hope these data will provide a
453 valuable resource for researchers and clinicians to gain insights to better characterise and identify

454 points of potential therapeutic intervention or immunological exacerbation in TB/COVID-19 co-
455 infected patients.

456

457 **Materials and Methods**

458 ***Mycobacterium tuberculosis* single cell stock generation**

459 *Mtb* single cell suspension stock for infection were made using *Mtb* lineage 2 clinical strain MRC57,
460 as previously described¹². Briefly, 10 mL 7H9 (Difco™ Middlebrook 7H9 broth, Becton
461 Dickinson)/ADC (Becton Dickinson) media containing 0.05% Tween-80 (Sigma-Aldrich) were
462 inoculated with *Mtb*. After 10 days growth at 37°C, 1 ml culture was subcultured into 100 mL
463 7H9/ADC media without Tween-80 and incubated at 37°C for a further 10 days. *Mtb* was pelleted by
464 centrifugation, and then single cell suspensions made by shaking with ~10 glass beads (2–3 mm,
465 Sigma-Aldrich) with successive washes in PBS and low speed centrifugation. Stocks were made in
466 PBS/5% glycerol and stored at -80°C. One fresh and one frozen aliquot was serially diluted and
467 plated in quadruplicated on three-sector 7H10 (Difco™ Middlebrook 7H10 agar, Becton
468 Dickinson)/ADC plates for colony forming unit (CFU) determination, incubated at 37°C and counted
469 after 10, 14 and 21 days.

470 **SARS-CoV-2 stock preparation**

471 SARS-CoV-2 stocks for infections were made using isolate VIC001 (24/03/21, obtained from The
472 Peter Doherty Institute for Infection and Immunity, Melbourne, Australia), as previously described¹².
473 Briefly, vero (CCL-81, ATCC) cells were cultured in Dulbecco's Modified Eagle Medium (DMEM
474 + 1 g/L D-glucose, L-glutamine and 110 mg/L sodium pyruvate) + 10% heat-inactivated foetal
475 bovine serum (FBS) until confluent. After washing in PBS, 2.5 mL serum-free DMEM containing

476 SARS-CoV-2 MOI of 0.01 (1×10^5 tissue culture infectious dose 50 (TCID₅₀) for $\sim 1 \times 10^7$ cells)
477 and 1 $\mu\text{g}/\text{mL}$ TPCK-treated trypsin was added and cells incubated at 37°C with 5% CO₂ for 30
478 minutes. 20 mL of serum-free DMEM + TPCK trypsin was added to the flask and incubated at 37°C
479 with 5% CO₂ for 48 hours or until sufficient cytopathic effect was observed under the microscope.
480 Infection media was centrifuged to pellet debris and 1 ml aliquots of supernatants stored at -80°C. To
481 determine infection stock TCID₅₀, vero cells were seeded in flat-bottomed 96-well plates at 1×10^4
482 cells/well and incubated at 37°C with 5% CO₂ overnight to achieve confluency. Cells were washed
483 twice with PBS and then cultured in 5-step 1:7 serial dilutions with six replicates/dilution in serum-
484 free DMEM + TPCK and incubated for four days at 37°C with 5% CO₂. TCID₅₀ values were
485 calculated by scoring wells (positive or negative) for cytopathic effect (CPE) on day four, using the
486 Spearman and Kärber method⁴⁷.

487 **Blood collection**

488 Acquisition of human blood samples and immunological investigations were approved by the Human
489 Research Ethics Committee at the Walter and Eliza Hall Institute (WEHI HREC #18_09LR and
490 #20/08) and Melbourne Health (RMH69108) as part of the COVID PROFILE study, a longitudinal
491 cohort of convalescent COVID-19 patients and uninfected contacts⁴⁸. Sample and study data were
492 collected and managed using REDCap^{49,50} electronic data capture tools hosted by Clinical Discovery
493 and Translation, WEHI, Parkville, Victoria, Australia. All subjects provided written informed
494 consent to participate in this study, in accordance with the Declaration of Helsinki. Participants were
495 selected to represent broad demographics of the population: equal age, sex and previous COVID-19
496 distribution, all COVID-19 vaccinated. Blood was collected in sodium heparin tubes from four
497 healthy participants (2 males [29/47 yrs] and 2 females [23/45 yrs]), three of whom self-identified as
498 being Oceanian (e.g. Australian, Aboriginal, Maori) and one (older female) as People of the
499 Americas (e.g. Hispanic, Brazilian, Mexican, Jamaican). All four had received 2 doses of either

500 Comirnaty (Pfizer/BioNTech) or ChAdOx1-S (Oxford/AstraZeneca). Blood from each participant
501 were divided into eight 500 μ L aliquots (approximately 2.5×10^6 cells/aliquot) for two timepoints (24
502 and 96 hours) and four conditions – uninfected, *Mtb*-infected, SARS-infected and co-infected in 10
503 ml tubes.

504 **Blood infections**

505 For SARS-CoV-2 infection, blood samples were pelleted at 300 x g for 10 minutes, plasma were
506 transferred to a sterile 2mL tube, cells were resuspended in 1 mL of 2.4×10^6 (TCID₅₀/mL) viral
507 particles of SARS-CoV-2 (MOI 1) in RPMI + TPCK trypsin and incubated at 37°C with 5% CO₂ for
508 30 minutes. After incubation, cells were pelleted, infection media removed, and autologous plasma
509 was replaced. For SARS-CoV-2 only infected samples, 500 μ L RPMI was then added. *Mtb*-only and
510 co-infected blood samples were infected with 500 μ L RPMI containing *Mtb* at 5.5×10^4 CFU/ml. An
511 equivalent volume of RPMI as also added to uninfected samples. All samples were placed on an
512 orbital rotator in a 37°C incubator with 5% CO₂ for 24 or 96 hours.

513 **Single-cell RNA-sequencing**

514 Cells were harvested at the appropriate timepoint by pelleting at 300 x g for 5 minutes, removing
515 supernatant, resuspending pellets in an appropriate volume of red blood cell lysis solution (0.15 M
516 NH₄Cl, 0.01 M KHCO₃, 0.1mM EDTA), incubating for 10 minutes and repeating with an RPMI
517 wash. Cells in a 1 mL RPMI suspension were counted using a Countess automated cell counter
518 (ThermoFisher). Equal numbers of cells from each of the four donors were combined in pairs (one
519 male and one female sample) for each condition and a total of 16 HIVE™ (Honeycomb
520 Biotechnologies) cell capture devices, two for each condition, were loaded with 30,000 total cells
521 according to manufacturer's instructions for cell preservation and storage at -80°C until ready for

522 further processing. The HIVE™ devices were processed to cDNA, after pooling conditions and
523 timepoints at equimolar concentrations to yield one indexed library for each condition and timepoint
524 (eight in total), according to manufacturer's instructions (v1 revision A). Final library concentrations
525 were measured using a KAPA Library Quantification Kit (KAPA Biosystems) and profiled on a
526 TapeStation (Agilent) before pooling at equimolar concentrations for Illumina NextSeq 2000
527 (Illumina) sequencing with custom primers (Honeycomb Biotechnologies), with the base calling and
528 quality scoring performed by the Real Time Analysis (v2.4.6) software.

529 **Data analysis**

530 The bespoke HIVE™ BeeNet™ pipeline (v1.1, Honeycomb Biotechnologies,
531 [https://honeycombbio.zendesk.com/hc/en-us/articles/4408694864283-BeeNet-v1-1-X-Software-](https://honeycombbio.zendesk.com/hc/en-us/articles/4408694864283-BeeNet-v1-1-X-Software-Guide)
532 [Guide](https://honeycombbio.zendesk.com/hc/en-us/articles/4408694864283-BeeNet-v1-1-X-Software-Guide)) was used to process the raw data into count matrices. First of all, the *make-ref* function was
533 used to generate a human reference genome index from the GRCh38 Homo sapiens reference
534 genome fasta and annotation gtf files (https://ftp.ensembl.org/pub/release-109/fasta/homo_sapiens/).
535 Fastq files were aligned to this index using the BeeNet™ *align* function and transcript count matrices
536 were obtained for each sample. To demultiplex the four donors combined in each sample, *cellsnp-*
537 *lite*⁵¹ was used to pileup expressed alleles in the data and *vireo*⁵² was subsequently used to assign
538 cells to donors. Donor ID probabilities obtained from these algorithms were used as metadata for
539 downstream analyses requiring biological replicates.

540 The Seurat pipeline was applied to count matrices for downstream analyses
541 (<https://satijalab.org/seurat/>). A Seurat object was created for each of the eight samples, combined
542 into a merged Seurat list and subjected to quality control filtration. Features with fewer than 50 genes
543 and 50 unique transcripts were removed and a threshold of <15% mitochondrial reads was used to
544 filter down to the final total cell numbers per sample for analysis. The low gene and transcript

545 thresholds were set to keep cell types with low numbers of expressed genes, particularly neutrophils,
546 in the analysis. Each object in the merged list was subjected to log normalization and variable feature
547 identification, using variance stabilising transformation and 2000 features⁵³. Objects were integrated
548 by selecting integration features, finding integration anchors based on these features and using the
549 integration anchors as input for the Seurat *IntegrateData* function⁵⁴. The resultant integrated data
550 object was scaled and subjected to principal component (PC) analysis before graph-based K-nearest
551 neighbour cluster identification was performed. Non-linear dimensionality reduction was performed
552 using uniform manifold approximation and projection (UMAP) on the first 10 dimensions.

553 Cell type annotation was conducted using SingleR and the Human Primary Cell Atlas Data obtained
554 via the *celldex* package⁵⁵. Cluster markers were identified by running the Seurat *FindAllMarkers*
555 function using the default Wilcoxon Rank-Sum test to define differentially expressed genes (DEG).
556 Gene ontology (GO) and Reactome pathway enrichment analysis were performed using the identified
557 markers and by invoking the *org.Hs.eg.db*, *AnnotationDbi* and *clusterProfiler* packages⁵⁶. A stringent
558 2-sided *p*-value cut-off of 0.001 was applied after Benjamini Hochberg adjustment for multiple
559 testing.

560 To perform pseudobulk differential expression analysis, the Seurat object was first converted to a
561 *SingleCellExperiment* class. Cluster counts and metadata for each donor were then aggregated and
562 extracted and used to create *DESeq2*⁵⁷ objects. Counts were transformed for clustering analyses
563 (Supplementary Fig. 4) before running the *DESeq* function. Log₂ fold-change (LFC) shrinkage and
564 Wald tests were performed for each contrast of interest to obtain results tables for all genes. Those
565 with false-discovery rate (FDR)-adjusted 2-sided *p*-values <0.05 and LFC values >0.58 were deemed
566 significant (Supplementary Table 5-10). GO analyses of pseudobulk data were performed using the
567 *clusterProfiler*⁵⁶ and *tmod*⁵⁸ packages.

568 **Data availability**

569 The raw fastq files and processed transcript count matrices for this study can be found in the gene
570 expression omnibus database under the accession number GSEXXXXXX. The scripts used to
571 analyse these data have been uploaded to GitHub - XXXXXX.

572 References

- 573 1 McQuaid, C. F., Vassall, A., Cohen, T., Fiekert, K. & White, R. G. The impact of COVID-19
574 on TB: a review of the data. *Int J Tuberc Lung Dis* **25**, 436-446 (2021).
- 575 2 Migliori, G. B. *et al.* Gauging the impact of the COVID-19 pandemic on tuberculosis
576 services: a global study. *European Respiratory Journal* **58**, 2101786 (2021).
- 577 3 World Health Organization. Global tuberculosis report 2022. (2022).
- 578 4 The TB/COVID-19 Global Study Group. Tuberculosis and COVID-19 co-infection:
579 description of the global cohort. *European Respiratory Journal* **59**, 2102538 (2022).
- 580 5 Western Cape Department of Health in collaboration with the National Institute for
581 Communicable Diseases South Africa. Risk Factors for Coronavirus Disease 2019 (COVID-
582 19) Death in a Population Cohort Study from the Western Cape Province, South Africa. *Clin*
583 *Infect Dis* **73**, e2005-e2015 (2021).
- 584 6 Petrone, L. *et al.* Coinfection of tuberculosis and COVID-19 limits the ability to in vitro
585 respond to SARS-CoV-2. *Int J Infect Dis* **113 Suppl 1**, S82-s87 (2021).
- 586 7 Riou, C. *et al.* Relationship of SARS-CoV-2-specific CD4 response to COVID-19 severity
587 and impact of HIV-1 and tuberculosis coinfection. *The Journal of Clinical Investigation* **131**
588 (2021).
- 589 8 Rajamanickam, A. *et al.* Latent tuberculosis co-infection is associated with heightened levels
590 of humoral, cytokine and acute phase responses in seropositive SARS-CoV-2 infection.
591 *Journal of Infection* **83**, 339-346 (2021).
- 592 9 Rajamanickam, A. *et al.* Effect of SARS-CoV-2 seropositivity on antigen – specific cytokine
593 and chemokine responses in latent tuberculosis. *Cytokine* **150**, 155785 (2022).
- 594 10 Hildebrand, R. E. *et al.* Superinfection with SARS-CoV-2 Has Deleterious Effects on
595 Mycobacterium bovis BCG Immunity and Promotes Dissemination of Mycobacterium
596 tuberculosis. *Microbiology Spectrum* **10**, e03075-03022 (2022).
- 597 11 Najafi-Fard, S. *et al.* Characterization of the immune impairment of tuberculosis and COVID-
598 19 coinfecting patients. *International Journal of Infectious Diseases* (2023).
- 599 12 Sheerin, D. *et al.* Immunopathogenic overlap between COVID-19 and tuberculosis identified
600 from transcriptomic meta-analysis and human macrophage infection. *iScience* **25**, 104464
601 (2022).
- 602 13 Cai, Y. *et al.* Single-cell transcriptomics of blood reveals a natural killer cell subset depletion
603 in tuberculosis. *EBioMedicine* **53** (2020).
- 604 14 Berry, M. P. R. *et al.* An interferon-inducible neutrophil-driven blood transcriptional
605 signature in human tuberculosis. *Nature* **466**, 973-977 (2010).
- 606 15 Bloom, C. I. *et al.* Transcriptional blood signatures distinguish pulmonary tuberculosis,
607 pulmonary sarcoidosis, pneumonias and lung cancers. *PLoS One* **8**, e70630 (2013).
- 608 16 Scriba, T. J. *et al.* Sequential inflammatory processes define human progression from M.
609 tuberculosis infection to tuberculosis disease. *PLoS Pathog* **13**, e1006687 (2017).
- 610 17 Schulte-Schrepping, J. *et al.* Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell
611 Compartment. *Cell* **182**, 1419-1440.e1423 (2020).

- 612 18 Silvin, A. *et al.* Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate
613 Severe from Mild COVID-19. *Cell* **182**, 1401-1418.e1418 (2020).
- 614 19 Cooper, A. M. *et al.* Disseminated tuberculosis in interferon gamma gene-disrupted mice. *J*
615 *Exp Med* **178**, 2243-2247 (1993).
- 616 20 Flynn, J. L. *et al.* An essential role for interferon gamma in resistance to Mycobacterium
617 tuberculosis infection. *J Exp Med* **178**, 2249-2254 (1993).
- 618 21 Flynn, J. L. *et al.* Tumor necrosis factor-alpha is required in the protective immune response
619 against Mycobacterium tuberculosis in mice. *Immunity* **2**, 561-572 (1995).
- 620 22 Karki, R. *et al.* Synergism of TNF- α and IFN- γ ; Triggers Inflammatory Cell
621 Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock
622 Syndromes. *Cell* **184**, 149-168.e117 (2021).
- 623 23 Li, S. *et al.* SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8
624 activation. *Signal Transduction and Targeted Therapy* **5**, 235 (2020).
- 625 24 André, S. *et al.* T cell apoptosis characterizes severe Covid-19 disease. *Cell Death &*
626 *Differentiation* **29**, 1486-1499 (2022).
- 627 25 Zhang, D. *et al.* Frontline Science: COVID-19 infection induces readily detectable
628 morphologic and inflammation-related phenotypic changes in peripheral blood monocytes. *J*
629 *Leukoc Biol* **109**, 13-22 (2021).
- 630 26 Lastrucci, C. *et al.* Tuberculosis is associated with expansion of a motile, permissive and
631 immunomodulatory CD16⁺ monocyte population via the IL-10/STAT3 axis. *Cell Res.* **25**,
632 1333-1351 (2015).
- 633 27 Hadjadj, J. *et al.* Impaired type I interferon activity and inflammatory responses in severe
634 COVID-19 patients. *Science* **369**, 718 (2020).
- 635 28 Arunachalam, P. S. *et al.* Systems biological assessment of immunity to mild versus severe
636 COVID-19 infection in humans. *Science* **369**, 1210-1220 (2020).
- 637 29 Israelow, B. *et al.* Mouse model of SARS-CoV-2 reveals inflammatory role of type I
638 interferon signaling. *J Exp Med* **217** (2020).
- 639 30 Zak, D. E. *et al.* A blood RNA signature for tuberculosis disease risk: a prospective cohort
640 study. *Lancet* **387**, 2312-2322 (2016).
- 641 31 Singhanian, A. *et al.* A modular transcriptional signature identifies phenotypic heterogeneity of
642 human tuberculosis infection. *Nat Commun* **9**, 2308 (2018).
- 643 32 Esmail, H. *et al.* Complement pathway gene activation and rising circulating immune
644 complexes characterize early disease in HIV-associated tuberculosis. *Proceedings of the*
645 *National Academy of Sciences* **115**, E964-E973 (2018).
- 646 33 Zhang, G. *et al.* A proline deletion in IFNAR1 impairs IFN-signaling and underlies increased
647 resistance to tuberculosis in humans. *Nature Communications* **9**, 85 (2018).
- 648 34 Desvignes, L., Wolf, A. J. & Ernst, J. D. Dynamic roles of type I and type II IFNs in early
649 infection with Mycobacterium tuberculosis. *J Immunol* **188**, 6205-6215 (2012).
- 650 35 Mesev, E. V., LeDesma, R. A. & Ploss, A. Decoding type I and III interferon signalling
651 during viral infection. *Nat Microbiol* **4**, 914-924 (2019).

- 652 36 Liu, J. *et al.* Longitudinal characteristics of lymphocyte responses and cytokine profiles in the
653 peripheral blood of SARS-CoV-2 infected patients. *eBioMedicine* **55** (2020).
- 654 37 Wilk, A. J. *et al.* A single-cell atlas of the peripheral immune response in patients with severe
655 COVID-19. *Nat. Med.* **26**, 1070-1076 (2020).
- 656 38 Pires, D. *et al.* Role of Cathepsins in Mycobacterium tuberculosis Survival in Human
657 Macrophages. *Sci Rep* **6**, 32247 (2016).
- 658 39 Zhang, Q. *et al.* Molecular mechanism of interaction between SARS-CoV-2 and host cells
659 and interventional therapy. *Signal Transduction and Targeted Therapy* **6**, 233 (2021).
- 660 40 Mathew, D. *et al.* Deep immune profiling of COVID-19 patients reveals distinct
661 immunotypes with therapeutic implications. *Science* **369** (2020).
- 662 41 Kuri-Cervantes, L. *et al.* Comprehensive mapping of immune perturbations associated with
663 severe COVID-19. *Sci Immunol* **5** (2020).
- 664 42 Ardain, A. *et al.* Group 3 innate lymphoid cells mediate early protective immunity against
665 tuberculosis. *Nature* **570**, 528-532 (2019).
- 666 43 Roy Chowdhury, R. *et al.* A multi-cohort study of the immune factors associated with M.
667 tuberculosis infection outcomes. *Nature* **560**, 644-648 (2018).
- 668 44 Allen, M. *et al.* Mechanisms of Control of Mycobacterium tuberculosis by NK Cells: Role of
669 Glutathione. *Front Immunol* **6**, 508 (2015).
- 670 45 Sefik, E. *et al.* Inflammasome activation in infected macrophages drives COVID-19
671 pathology. *Nature* **606**, 585-593 (2022).
- 672 46 Chang, J. J. *et al.* Long-Read RNA Sequencing Identifies Polyadenylation Elongation and
673 Differential Transcript Usage of Host Transcripts During SARS-CoV-2 In Vitro Infection.
674 *Front Immunol* **13**, 832223 (2022).
- 675 47 Ramakrishnan, M. A. Determination of 50% endpoint titer using a simple formula. *World J*
676 *Virol* **5**, 85-86 (2016).
- 677 48 Emily, M. E. *et al.* Cohort Profile: A longitudinal Victorian COVID-19 cohort (COVID
678 PROFILE). *medRxiv*, 2023.2004.2027.23289157 (2023).
- 679 49 Harris, P. A. *et al.* Research electronic data capture (REDCap)--a metadata-driven
680 methodology and workflow process for providing translational research informatics support. *J*
681 *Biomed Inform* **42**, 377-381 (2009).
- 682 50 Harris, P. A. *et al.* The REDCap consortium: Building an international community of
683 software platform partners. *J Biomed Inform* **95**, 103208 (2019).
- 684 51 Huang, X. & Huang, Y. Cellsnip-lite: an efficient tool for genotyping single cells.
685 *Bioinformatics* **37**, 4569-4571 (2021).
- 686 52 Huang, Y., McCarthy, D. J. & Stegle, O. Vireo: Bayesian demultiplexing of pooled single-
687 cell RNA-seq data without genotype reference. *Genome Biology* **20**, 273 (2019).
- 688 53 Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-seq
689 data using regularized negative binomial regression. *Genome Biol* **20**, 296 (2019).
- 690 54 Stuart, T. *et al.* Comprehensive Integration of Single-Cell Data. *Cell* **177**, 1888-1902.e1821
691 (2019).

- 692 55 Aran, D. *et al.* Reference-based analysis of lung single-cell sequencing reveals a transitional
693 profibrotic macrophage. *Nature Immunology* **20**, 163-172 (2019).
- 694 56 Wu, T. *et al.* clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. *The*
695 *Innovation* **2** (2021).
- 696 57 Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for
697 RNA-seq data with DESeq2. *Genome Biology* **15**, 550 (2014).
- 698 58 Zyla, J. *et al.* Gene set enrichment for reproducible science: comparison of CERNO and eight
699 other algorithms. *Bioinformatics* **35**, 5146-5154 (2019).

700

701 **Acknowledgments**

702 The authors thank Honeycomb Biotechnologies Inc. for allowing us to participate in their early
703 access program, Coussens Lab members for feedback, the WEHI PC3 Facility manager Kathryn
704 Davidson for facility support, the WEHI Genomics R&D team, especially Rory Bowden, Daniela
705 Zalcenstein, Daniel Brown and Ling Ling, for their input regarding experimental design and analysis,
706 the Pellegrini Lab at WEHI for providing Vero cells and input into SARS-CoV-2 assays, and Stephen
707 Wilcox of the WEHI Genomics Facility for performing Illumina sequencing of samples. D.S. is
708 supported by WEHI and NHMRC (2020750). A.K.C. is funded by WEHI, philanthropic donors,
709 NHMRC (2020750) and the Australian Respiratory Council. This work was made possible through
710 Victorian State Government Operational Infrastructure Support and Australian Government NHMRC
711 IRIISS. The COVID Profile study was supported by WHO Unity funds and WEHI Philanthropic
712 funds. The funders had no role in study design, data collection and analysis.

713 **Author Contributions**

714 D.S. and A.K.C. conceived and designed the study. E.E. directed the COVID PROFILE clinical
715 study, arranged blood sample collection, SARS-CoV-2 serotyping, and critically reviewed the
716 manuscript. A.K.C. and E.E. funded the study. T.K.P. generated SARS-CoV-2 virus stocks and
717 critically reviewed the manuscript. D.S. generated *Mtb* stocks. D.S. performed blood infection

718 experiments and processed samples for scRNA-seq. D.S. performed the data analysis. D.S. prepared
719 the manuscript with editorial input and revisions from A.K.C. All authors approved the manuscript
720 submission.

721 **Competing interests**

722 The authors declare no competing interests.